Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10206647 | 0.93 | CYP3A4 (0.42) | PPARGCHEK2MAOAMAOBPRMT5 | |
| Trifluoroacetic Acid SCHEMBL712377 | 0.91 | CHEK2 (0.45) | CHEK2PRMT5CYP3A4SCDDHODH | |
| Trifluoroacetic Acid SCHEMBL711040 | 0.87 | DHODH (0.45) | CHEK2PRMT5DHODH | |
| Trifluoroacetic Acid SCHEMBL713011 | 0.86 | GCK (0.44) | CHEK2NOS1PRMT5SCDDHODH | |
| Trifluoroacetic Acid SCHEMBL712661 | 0.86 | CHEK2 (0.41) | CHEK2PRMT5CYP3A4SCDDHODH | |
| Trifluoroacetic Acid SCHEMBL710265 | 0.86 | MAOB (0.39) | PPARGCHEK2MAOAMAOBCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL711105 | 0.84 | CYP1A1 (0.41) | CHEK2PRMT5SCDDHODH | |
| Trifluoroacetic Acid SCHEMBL711953 | 0.83 | CHEK2 (0.40) | CHEK2PRMT5SCDDHODH | |
| Trifluoroacetic Acid SCHEMBL709196 | 0.83 | FFAR1 (0.42) | CHEK2PRMT5CYP3A4DHODH | |
| SCHEMBL10206641 | 0.82 | PRMT5 (0.51) | CHEK2PRMT5CYP3A4DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | PPARG 991/4885CHEK2 1189/4885NOS1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.